Category Research

Vertex Secures CASGEVY® Reimbursement Agreement for Sickle Cell Disease Treatment in England

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that it has secured a reimbursement agreement with NHS England, providing eligible sickle cell disease (SCD) patients access to its groundbreaking CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement represents a significant advancement in…

Read MoreVertex Secures CASGEVY® Reimbursement Agreement for Sickle Cell Disease Treatment in England

Owkin Administers First Dose in AI-Optimized Phase I Trial of OKN4395 for Solid Tumors

Owkin Achieves Milestone with First Patient Dosed in AI-Optimized Phase I Trial of OKN4395, a First-in-Class Triple Inhibitor for Solid Tumors On January 22, 2025, Owkin, the pioneering end-to-end AI biotech company transforming drug discovery, development, and diagnostics through agent-based…

Read MoreOwkin Administers First Dose in AI-Optimized Phase I Trial of OKN4395 for Solid Tumors

New Analysis: Medicare Drug Price Negotiation Program Threatens U.S. Pharmacy Stability

Medicare Drug Price Negotiation Program Sparks Concerns Over Pharmacy Viability and Patient Access The National Community Pharmacists Association (NCPA) has issued an urgent call for the immediate suspension of the Medicare Drug Price Negotiation Program (MDPNP), citing its potential to…

Read MoreNew Analysis: Medicare Drug Price Negotiation Program Threatens U.S. Pharmacy Stability

Science Exchange Unveils Innovative Clinical Development Solution for Enhanced Research Efficiency

Revolutionizing Clinical Development: Science Exchange Launches Cutting-Edge Supplier Orchestration Solution In today’s rapidly evolving life sciences landscape, clinical development teams face mounting pressure to manage increasingly complex outsourcing arrangements. From functional service provider (FSP) models to full-service outsourcing (FSO), the…

Read MoreScience Exchange Unveils Innovative Clinical Development Solution for Enhanced Research Efficiency

Biological Drugs Market to Hit $634.4 Billion by 2030, Fueled by Healthcare Expansion and Chronic Disease Surge

The “Biological Drugs – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offerings, providing an in-depth analysis of the market’s current landscape, trends, and future projections. The global biological drugs market was valued at approximately USD 345.3 billion in…

Read MoreBiological Drugs Market to Hit $634.4 Billion by 2030, Fueled by Healthcare Expansion and Chronic Disease Surge

Dr. Stephanie Simmons of Photonic Inc. to Headline UNESCO’s Quantum Science and Technology Launch Event

Photonic Inc. Founder Dr. Stephanie Simmons to Speak at UNESCO’s International Year of Quantum Science and Technology Opening Ceremony Paris, France – February 4-5, 2025 – Photonic Inc., a global leader in distributed quantum computing using silicon-based technologies, has announced…

Read MoreDr. Stephanie Simmons of Photonic Inc. to Headline UNESCO’s Quantum Science and Technology Launch Event

Sarclisa Approved in EU for Treating Transplant-Ineligible Newly Diagnosed Multiple Myeloma

European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has approved Sarclisa in combination with a standard-of-care regimen—bortezomib, lenalidomide, and dexamethasone (VRd)—for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) ineligible for…

Read MoreSarclisa Approved in EU for Treating Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Medical Device Breakthrough WuXi AppTec to Strategically Sell U.S. Testing Operations to NAMSA

Impact on WuXi AppTec’s Operations WuXi AppTec, a global leader in providing comprehensive R&D and manufacturing services for the pharmaceutical and life sciences industries, recently announced the signing of a definitive agreement to sell its U.S. medical device testing operations…

Read MoreMedical Device Breakthrough WuXi AppTec to Strategically Sell U.S. Testing Operations to NAMSA